R Squared’s Viridian Therapeutics VRDN Stock Holding History

R Squared’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,340	Closed	-$25.7K	–	1494
2024 Q4	$25.7K	Buy	+1,340	New	+$29.1K	0.03%	767

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

R Squared's VRDN Position: Q1 2025 in Review

R Squared sold out of Viridian Therapeutics (VRDN) in Q1 2025, closing a stake of 1,340 shares — an estimated $25.7K sold.

R Squared first reported a position in VRDN in Q4 2024 and held it in 1 quarter. The position peaked at $25.7K in Q4 2024. 176 funds tracked by Wall St. Rank hold VRDN as of Q1 2025.

R Squared reported no remaining Viridian Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,340 Viridian Therapeutics shares in Q1 2025, an estimated $25.7K.
R Squared first reported a position in Viridian Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Viridian Therapeutics position peaked at $25.7K in Q4 2024.
176 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.